Table 2.
Comparison of detection rates of cytokines and chemokines between patients with disease control and patients with progressive disease during FOLFIRINOX, measured with a multiplex Luminex panel.
| Before start of FOLFIRINOX | |||
|---|---|---|---|
| Cytokine/chemokine | Detection rate disease control (%), n=64 | Detection rate progressive disease (%), n=19 | P |
| IFN-γ | 4 (6) | 1 (5) | 1.000 |
| IL-1α | 12 (19) | 4 (21) | 1.000 |
| IL-1β | 18 (28) | 1 (5) | 0.059 |
| IL-1RA | 2 (3) | 1 (5) | 0.547 |
| IL-2 | 12 (19) | 0 (0) | 0.059 |
| IL-6 | 1 (2) | 1 (5) | 0.408 |
| IL-7 | 45 (70) | 14 (74) | 1.000 |
| IL-10 | 2 (3) | 0 (0) | 1.000 |
| IL-15 | 6 (9) | 0 (0) | 0.328 |
| IL-17A | 13 (20) | 1 (5) | 0.172 |
| IL-18 | 29 (45) | 6 (32) | 0.428 |
| IL-21 | 6 (9) | 1 (5) | 1.000 |
| IL-22 | 5 () | 0 (0) | 0.584 |
| IL-27 | 5 (78) | 0 (0) | 0.584 |
| MCP-1 | 62 (97) | 18 (95) | 0.547 |
| MIP-1α | 18 (28) | 5 (26) | 1.000 |
| TNF-α | 10 (16) | 0 (0) | 0.107 |
| After 1 cycle of FOLFIRINOX | |||
| Cytokine/chemokine | Detection rate disease control (%), n=64 | Detection rate progressive disease (%), n=19 | P |
| IFN-γ | 6 (9) | 1 (5) | 1.000 |
| IL-1α | 11 (17) | 3 (16) | 1.000 |
| IL-1β | 14 (21) | 4 (21) | 1.000 |
| IL-1RA | 31 (48) | 4 (21) | 0.038a |
| IL-2 | 10 (16) | 0 (0) | 0.107 |
| IL-6 | 4 (6) | 2 (11) | 0.616 |
| IL-7 | 45 (70) | 13 (68) | 1.000 |
| IL-10 | 3 (5) | 0 (0) | 1.000 |
| IL-15 | 4 (6) | 0 (0) | 0.569 |
| IL-17A | 14 (22) | 2 (11) | 0.340 |
| IL-18 | 44 (69) | 11 (58) | 0.416 |
| IL-21 | 4 (6) | 2 (11) | 0.616 |
| IL-22 | 4 (6) | 1 (5) | 1.000 |
| IL-27 | 5 (8) | 0 (0) | 0.584 |
| MCP-1 | 62 (97) | 17 (90) | 0.223 |
| MIP-1α | 13 (20) | 4 (21) | 1.000 |
| TNF-α | 8 (13) | 1 (5) | 0.677 |
IFN, interferon; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; IP-10, interferon gamma-induced protein 10; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor. aSignificant P-value.
P-values are calculated by Fisher’s exact tests.